Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer
NCT04390945
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
62
Enrollment
OTHER
Sponsor class
Conditions
Esophageal Cancer
Interventions
DRUG:
Camrelizumab
Sponsor
The First Affiliated Hospital of Henan University of Science and Technology